PeptideStack
5.2kquestions
20kanswers
220users

How does survodutide at 2.4 mg weekly compare on cost per milligram across routes?

Asked 27 May 2026Modified 18 days agoViewed 4.8k times
3

Concretely: survodutide · 2.4 mg.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Is my approach right even if my number is wrong?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
ZA
askedzeynep_arslan16k2627 May 2026

5 Answers

Accepted answer first, then by votes
23

Accepted answer

2.4 mg a week is 125 mg a year and 10.4 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 125 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

The honest answer is that the cheapest headline price is frequently not the cheapest outcome.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.

Decide whether you are optimising cost or confidence before you build the model.

edited 12 Jul 2026 by t_oyelaran — corrected a unit error in the worked example

shareimprove this answerflag
TO
answered · acceptedt_oyelaran79k4825 Jun 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
19

Answering this needs the order size, because carriage and testing amortise very differently across one vial and across ten.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Independent testing prices at the services this community uses are published and are stable enough to model.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
AM
answeredaine_mulcahy28k2722 Jun 2026
9

More usefully, wastage from expired reconstituted vials is a real line item and nobody includes it.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
DC
answeredDr_Idris_Coulibaly33k13716 Jun 2026
6Small correction: carriage amortises across the order, which changes small-order economics entirely. – tess_amankwah 36 days ago
7Is there a sensible order size where independent testing stops being a large surcharge? – h_pergande 3 months ago
add a comment
8

The relevant arithmetic is that a fifteen per cent price advantage disappears against a ten per cent content shortfall plus a testing cost.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
TM
answeredtobias_maartens171k3589 Jun 2026
7

This is a spreadsheet question and doing it properly changes conclusions more often than people expect.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
TO
answeredt_oyelaran79k4819 Jun 2026
4Thank you — this is the answer I was looking for. – Dr_Colm_Fitzhenry 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.